Publications

Peer-Reviewed Publications (1996-2014)

  1. Deaglio S, Dianzani U, Horenstein AL, Fernandez JE, van Kooten C, Bragardo M, Funaro A, Garbarino G, Di Virgilio F, Banchereau J, Malavasi F (1996) Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells. J Immunol 156: 727-734.
  2. Cesano A, Visonneau S, Deaglio S, Malavasi F, Santoli D (1998) Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells. J Immunol 160: 1106-1115.
  3. Deaglio S, Morra M, Mallone R, Ausiello CM, Prager E, Garbarino G, Dianzani U, Stockinger H, Malavasi F (1998) Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol 160: 395-402.
  4. Fernandez JE, Deaglio S, Donati D, Beusan IS, Corno F, Aranega A, Forni M, Falini B, Malavasi F (1998) Analysis of the distribution of human CD38 and of its ligand CD31 in normal tissues. J Biol Regul Homeost Agents 12: 81-91.
  5. Baj G, Arnulfo A, Deaglio S, Tibaldi E, Surico N, Malavasi F (1999) All-trans retinoic acid inhibits the growth of breast cancer cells by up-regulating ICAM-1 expression. J Biol Regul Homeost Agents 13: 115-122.
  6. Vallario A, Chilosi M, Adami F, Montagna L, Deaglio S, Malavasi F, Caligaris-Cappio F (1999) Human myeloma cells express the CD38 ligand CD31. Br J Haematol 105: 441-444.
  7. Ausiello CM, Urbani F, Lande R, la Sala A, Di Carlo B, Baj G, Surico N, Hilgers J, Deaglio S, Funaro A, Malavasi F (2000) Functional topography of discrete domains of human CD38. Tissue Antigens 56: 539-547.
  8. Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, Rosa M, Giana M, Villa L, Malavasi F, Surico N (2000) Retinoids in breast cancer prevention and treatment. A review of the literature. Eur J Gynaecol Oncol 21: 411-415.
  9. Cassoni P, Fulcheri E, Carcangiu ML, Stella A, Deaglio S, Bussolati G (2000) Oxytocin receptors in human adenocarcinomas of the endometrium: presence and biological significance. J Pathol 190: 470-477.
  10. Deaglio S, Mallone R, Baj G, Arnulfo A, Surico N, Dianzani U, Mehta K, Malavasi F (2000) CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes. Chem Immunol 75: 99-120.
  11. Zilber MT, Gregory S, Mallone R, Deaglio S, Malavasi F, Charron D, Gelin C (2000) CD38 expressed on human monocytes: a coaccessory molecule in the superantigen-induced proliferation. Proc Natl Acad Sci U S A 97: 2840-2845.
  12. Cassoni P, Marrocco T, Deaglio S, Sapino A, Bussolati G (2001) Biological relevance of oxytocin and oxytocin receptors in cancer cells and primary tumors. Ann Oncol 12 Suppl 2: S37-39.
  13. Cassoni P, Sapino A, Munaron L, Deaglio S, Chini B, Graziani A, Ahmed A, Bussolati G (2001) Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines. Endocrinology 142: 1130-1136.
  14. Deaglio S, Canella D, Baj G, Arnulfo A, Waxman S, Malavasi F (2001) Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells. Leuk Res 25: 227-235.
  15. Deaglio S, Mallone R, Baj G, Donati D, Giraudo G, Corno F, Bruzzone S, Geuna M, Ausiello C, Malavasi F (2001) Human CD38 and its ligand CD31 define a unique lamina propria T lymphocyte signaling pathway. FASEB J 15: 580-582.
  16. Deaglio S, Mehta K, Malavasi F (2001) Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res 25: 1-12.
  17. Morabito F, Mangiola M, Oliva B, Stelitano C, Callea V, Deaglio S, Iacopino P, Brugiatelli M, Malavasi F (2001) Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia. Leuk Res 25: 927-932.
  18. Musso T, Deaglio S, Franco L, Calosso L, Badolato R, Garbarino G, Dianzani U, Malavasi F (2001) CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines. J Leukoc Biol 69: 605-612.
  19. Sapino A, Bongiovanni M, Cassoni P, Righi L, Arisio R, Deaglio S, Malavasi F (2001) Expression of CD31 by cells of extensive ductal in situ and invasive carcinomas of the breast. J Pathol 194: 254-261.
  20. Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, Surico N, Malavasi F, Ferrero E (2002) Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 73: 61-73.
  21. Cassoni P, Sapino A, Deaglio S, Bussolati B, Volante M, Munaron L, Albini A, Torrisi A, Bussolati G (2002) Oxytocin is a growth factor for Kaposi's sarcoma cells: evidence of endocrine-immunological cross-talk. Cancer Res 62: 2406-2413.
  22. Deaglio S, Capobianco A, Cali A, Bellora F, Alberti F, Righi L, Sapino A, Camaschella C, Malavasi F (2002) Structural, functional, and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum. Blood 100: 3782-3789.
  23. Deaglio S, Zubiaur M, Gregorini A, Bottarel F, Ausiello CM, Dianzani U, Sancho J, Malavasi F (2002) Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells. Blood 99: 2490-2498.
  24. Gregorini A, Cinti C, Pigliapoco F, Deaglio S, Ferrero E, Papa S, Palma F (2002) Rapid and sensitive detection of recombinant soluble proteins in the supernatant of transfected mammalian cells. J Biol Regul Homeost Agents 16: 93-97.
  25. Lande R, Urbani F, Di Carlo B, Sconocchia G, Deaglio S, Funaro A, Malavasi F, Ausiello CM (2002) CD38 ligation plays a direct role in the induction of IL-1beta, IL-6, and IL-10 secretion in resting human monocytes. Cell Immunol 220: 30-38.
  26. Morabito F, Mangiola M, Stelitano C, Deaglio S, Callea V, Malavasi F (2002) Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucil. Haematologica 87: 217-218.
  27. Deaglio S, Capobianco A, Bergui L, Durig J, Morabito F, Duhrsen U, Malavasi F (2003) CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 102: 2146-2155.
  28. Durig J, Nuckel H, Huttmann A, Kruse E, Holter T, Halfmeyer K, Fuhrer A, Rudolph R, Kalhori N, Nusch A, Deaglio S, Malavasi F, Moroy T, Klein-Hitpass L, Duhrsen U (2003) Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. Blood 101: 2748-2755.
  29. Morabito F, Mangiola M, Stelitano C, Deaglio S, Callea V, Malavasi F (2003) Simultaneous expression of CD38 and its ligand CD31 by chronic lymphocytic leukemia B-cells: anecdotal observation or pathogenetic hypothesis for the clinical outcome? Haematologica 88: 354-355.
  30. Righi L, Deaglio S, Pecchioni C, Gregorini A, Horenstein AL, Bussolati G, Sapino A, Malavasi F (2003) Role of CD31/platelet endothelial cell adhesion molecule-1 expression in in vitro and in vivo growth and differentiation of human breast cancer cells. Am J Pathol 162: 1163-1174.
  31. Savarino A, Bensi T, Chiocchetti A, Bottarel F, Mesturini R, Ferrero E, Calosso L, Deaglio S, Ortolan E, Butto S, Cafaro A, Katada T, Ensoli B, Malavasi F, Dianzani U (2003) Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120. FASEB J 17: 461-463.
  32. Tenca C, Merlo A, Zarcone D, Saverino D, Bruno S, De Santanna A, Ramarli D, Fabbi M, Pesce C, Deaglio S, Ciccone E, Malavasi F, Grossi CE (2003) Death of T cell precursors in the human thymus: a role for CD38. Int Immunol 15: 1105-1116.
  33. Calzolari A, Deaglio S, Sposi NM, Petrucci E, Morsilli O, Gabbianelli M, Malavasi F, Peschle C, Testa U (2004) Transferrin receptor 2 protein is not expressed in normal erythroid cells. Biochem J 381: 629-634.
  34. Deaglio S, Vaisitti T, Bergui L, Bonello L, Horenstein AL, Tamagnone L, Boumsell L, Malavasi F (2005) CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 105: 3042-3050.
  35. Isoardo G, Deaglio S, Cocito D, Migliaretti G, Ferrero E, Cavallo F, Durelli L, Malavasi F (2005) Immunodetection of anti-MAG IgM antibody by cross-reactivity to LA-N-1 neuroblastoma cells. J Neuroimmunol 161: 78-86.
  36. Vaisitti T, Deaglio S, Malavasi F (2005) Cationization of monoclonal antibodies: another step towards the "magic bullet"? J Biol Regul Homeost Agents 19: 105-112.
  37. Calzolari A, Raggi C, Deaglio S, Sposi NM, Stafsnes M, Fecchi K, Parolini I, Malavasi F, Peschle C, Sargiacomo M, Testa U (2006) TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci 119: 4486-4498.
  38. Deaglio S, Malavasi F (2006) The CD38/CD157 mammalian gene family: An evolutionary paradigm for other leukocyte surface enzymes. Purinergic Signal 2: 431-441.
  39. Deaglio S, Vaisitti T, Aydin S, Ferrero E, Malavasi F (2006) In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 108: 1135-1144.
  40. Frasca L, Fedele G, Deaglio S, Capuano C, Palazzo R, Vaisitti T, Malavasi F, Ausiello CM (2006) CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells. Blood 107: 2392-2399.
  41. Malavasi F, Deaglio S, Ferrero E, Funaro A, Sancho J, Ausiello CM, Ortolan E, Vaisitti T, Zubiaur M, Fedele G, Aydin S, Tibaldi EV, Durelli I, Lusso R, Cozno F, Horenstein AL (2006) CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity. Mol Med 12: 334-341.
  42. Morabito F, Damle RN, Deaglio S, Keating M, Ferrarini M, Chiorazzi N (2006) The CD38 ectoenzyme family: advances in basic science and clinical practice. Mol Med 12: 342-344.
  43. Calzolari A, Oliviero I, Deaglio S, Mariani G, Biffoni M, Sposi NM, Malavasi F, Peschle C, Testa U (2007) Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis 39: 82-91.
  44. D'Arena G, Tarnani M, Rumi C, Vaisitti T, Aydin S, De Filippi R, Perrone F, Pinto A, Chiusolo P, Deaglio S, Malavasi F, Laurenti L (2007) Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. Am J Hematol 82: 787-791.
  45. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204: 1257-1265.
  46. Deaglio S, Vaisitti T, Aydin S, Bergui L, D'Arena G, Bonello L, Omede P, Scatolini M, Jaksic O, Chiorino G, Efremov D, Malavasi F (2007) CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 110: 4012-4021.
  47. Deaglio S, Vaisitti T, Billington R, Bergui L, Omede P, Genazzani AA, Malavasi F (2007) CD38/CD19: a lipid raft-dependent signaling complex in human B cells. Blood 109: 5390-5398.
  48. Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, Robson SC (2007) CD39 and control of cellular immune responses. Purinergic Signal 3: 171-180.
  49. Willimott S, Baou M, Huf S, Deaglio S, Wagner SD (2007) Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4. Haematologica 92: 1359-1366.
  50. Aydin S, Rossi D, Bergui L, D'Arena G, Ferrero E, Bonello L, Omede P, Novero D, Morabito F, Carbone A, Gaidano G, Malavasi F, Deaglio S (2008) CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood 111: 5646-5653.
  51. Deaglio S, Aydin S, Vaisitti T, Bergui L, Malavasi F (2008) CD38 at the junction between prognostic marker and therapeutic target. Trends Mol Med 14: 210-218.
  52. Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, Vaisitti T, Aydin S (2008) Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 88: 841-886.
  53. Sitkovsky M, Lukashev D, Deaglio S, Dwyer K, Robson SC, Ohta A (2008) Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol 153 Suppl 1: S457-464.
  54. Calzolari A, Deaglio S, Maldi E, Cassoni P, Malavasi F, Testa U (2009) TfR2 expression in human colon carcinomas. Blood Cells Mol Dis 43: 243-249.
  55. Calzolari A, Finisguerra V, Oliviero I, Deaglio S, Mariani G, Malavasi F, Testa U (2009) Regulation of transferrin receptor 2 in human cancer cell lines. Blood Cells Mol Dis 42: 5-13.
  56. Dal-Bo M, Bertoni F, Forconi F, Zucchetto A, Bomben R, Marasca R, Deaglio S, Laurenti L, Efremov DG, Gaidano G, Del Poeta G, Gattei V (2009) Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med 7: 76.
  57. De Martino L, D'Arena G, Minervini MM, Deaglio S, Fusco BM, Cascavilla N, De Feo V (2009) Verbena officinalis essential oil and its component citral as apoptotic-inducing agent in chronic lymphocytic leukemia. Int J Immunopathol Pharmacol 22: 1097-1104.
  58. Deaglio S, Malavasi F (2009) Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. Haematologica 94: 752-756.
  59. Horenstein AL, Sizzano F, Lusso R, Besso FG, Ferrero E, Deaglio S, Corno F, Malavasi F (2009) CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus. Mol Med 15: 76-84.
  60. Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, De Paoli L, Laurenti L, Maffei R, Forconi F, Bertoni F, Zucca E, Agostinelli C, Cabras A, Lucioni M, Martini M, Magni M, Deaglio S, Ladetto M, Nomdedeu JF, Besson C, Ramponi A, Canzonieri V, Paulli M, Marasca R, Larocca LM, Carbone A, Pileri SA, Gattei V, Gaidano G (2009) Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res 15: 4415-4422.
  61. Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal Bo M, Marconi D, Bossi F, Lorenzon D, Degan M, Rossi FM, Rossi D, Bulian P, Franco V, Del Poeta G, Deaglio S, Gaidano G, Tedesco F, Malavasi F, Gattei V (2009) CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 69: 4001-4009.
  62. Calzolari A, Larocca LM, Deaglio S, Finisguerra V, Boe A, Raggi C, Ricci-Vitani L, Pierconti F, Malavasi F, De Maria R, Testa U, Pallini R (2010) Transferrin receptor 2 is frequently and highly expressed in glioblastomas. Transl Oncol 3: 123-134.
  63. D'Arena G, Capalbo S, Laurenti L, Del Poeta G, Nunziata G, Deaglio S, Spinosa G, Tarnani M, De Padua L, Califano C, Ferrara F, Cascavilla N (2010) Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. Eur J Haematol 85: 502-507.
  64. Deaglio S, Aydin S, Grand MM, Vaisitti T, Bergui L, D'Arena G, Chiorino G, Malavasi F (2010) CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol Med 16: 87-91.
  65. Deaglio S, Vaisitti T, Zucchetto A, Gattei V, Malavasi F (2010) CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells. Semin Cancer Biol 20: 416-423.
  66. Dwyer KM, Hanidziar D, Putheti P, Hill PA, Pommey S, McRae JL, Winterhalter A, Doherty G, Deaglio S, Koulmanda M, Gao W, Robson SC, Strom TB (2010) Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant 10: 2410-2420.
  67. Malavasi F, Deaglio S, Zaccarello G, Horenstein AL, Chillemi A, Audrito V, Serra S, Gandione M, Zitella A, Tizzani A (2010) The hidden life of NAD+-consuming ectoenzymes in the endocrine system. J Mol Endocrinol 45: 183-191.
  68. Pearce L, Morgan L, Lin TT, Hewamana S, Matthews RJ, Deaglio S, Rowntree C, Fegan C, Pepper C, Brennan P (2010) Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38. Haematologica 95: 514-517.
  69. Vaisitti T, Aydin S, Rossi D, Cottino F, Bergui L, D'Arena G, Bonello L, Horenstein AL, Brennan P, Pepper C, Gaidano G, Malavasi F, Deaglio S (2010) CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 24: 958-969.
  70. Zucchetto A, Tripodo C, Benedetti D, Deaglio S, Gaidano G, Del Poeta G, Gattei V (2010) Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38(+)CD49d(+) chronic lymphocytic leukaemia cells. Br J Haematol 150: 111-113.
  71. Audrito V, Vaisitti T, Rossi D, Gottardi D, D'Arena G, Laurenti L, Gaidano G, Malavasi F, Deaglio S (2011) Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res 71: 4473-4483.
  72. . Bulian P, Tarnani M, Rossi D, Forconi F, Del Poeta G, Bertoni F, Zucca E, Montillo M, Pozzato G, Deaglio S, D'Arena G, Efremov D, Marasca R, Lauria F, Gattei V, Gaidano G, Laurenti L (2011) Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. Hematol Oncol 29: 91-99.
  73. Crowther-Swanepoel D, Di Bernardo MC, Jamroziak K, Karabon L, Frydecka I, Deaglio S, D'Arena G, Rossi D, Gaidano G, Olver B, Lloyd A, Broderick P, Laurenti L, Szemraj-Rogucka Z, Robak T, Catovsky D, Houlston RS (2011) Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk. Br J Haematol 154: 229-233.
  74. D'Arena G, Deaglio S, Laurenti L, De Martino L, De Feo V, Fusco BM, Carella AM, Cascavilla N, Musto P (2011) Targeting regulatory T cells for anticancer therapy. Mini Rev Med Chem 11: 480-485.
  75. D'Arena G, Laurenti L, Minervini MM, Deaglio S, Bonello L, De Martino L, De Padua L, Savino L, Tarnani M, De Feo V, Cascavilla N (2011) Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 35: 363-368.
  76. D'Arena G, Rossi G, Minervini MM, Savino L, D'Auria F, Laurenti L, Del Principe MI, Deaglio S, Biagi A, De Martino L, De Feo V, Statuto T, Musto P, Del Poeta G (2011) Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis. Int J Immunopathol Pharmacol 24: 915-923.
  77. Deaglio S, Robson SC (2011) Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv Pharmacol 61: 301-332.
  78. Deaglio S, Vaisitti T, Serra S, Audrito V, Bologna C, D'Arena G, Laurenti L, Gottardi D, Malavasi F (2011) CD38 in chronic lymphocytic leukemia: from bench to bedside? Mini Rev Med Chem 11: 503-507.
  79. Ferretti E, Bertolotto M, Deaglio S, Tripodo C, Ribatti D, Audrito V, Blengio F, Matis S, Zupo S, Rossi D, Ottonello L, Gaidano G, Malavasi F, Pistoia V, Corcione A (2011) A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. Leukemia 25: 1268-1277.
  80. Kunzli BM, Berberat PO, Dwyer K, Deaglio S, Csizmadia E, Cowan P, d'Apice A, Moore G, Enjyoji K, Friess H, Robson SC (2011) Variable impact of CD39 in experimental murine colitis. Dig Dis Sci 56: 1393-1403.
  81. Laurenti L, De Padua L, D'Arena G, Vannata B, Innocenti I, Tarnani M, Deaglio S, Sica S, Efremov DG, Leone G (2011) New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Mini Rev Med Chem 11: 508-518.
  82. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N (2011) CD38 and chronic lymphocytic leukemia: a decade later. Blood 118: 3470-3478.
  83. Pezzolo A, Parodi F, Marimpietri D, Raffaghello L, Cocco C, Pistorio A, Mosconi M, Gambini C, Cilli M, Deaglio S, Malavasi F, Pistoia V (2011) Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. Cell Res 21: 1470-1486.
  84. Rasi S, Spina V, Bruscaggin A, Vaisitti T, Tripodo C, Forconi F, De Paoli L, Fangazio M, Sozzi E, Cencini E, Laurenti L, Marasca R, Visco C, Xu-Monette ZY, Gattei V, Young KH, Malavasi F, Deaglio S, Gaidano G, Rossi D (2011) A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 152: 284-294.
  85. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M, Fangazio M, Vaisitti T, Monti S, Chiaretti S, Guarini A, Del Giudice I, Cerri M, Cresta S, Deambrogi C, Gargiulo E, Gattei V, Forconi F, Bertoni F, Deaglio S, Rabadan R, Pasqualucci L, Foa R, Dalla-Favera R, Gaidano G (2011) Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 118: 6904-6908.
  86. Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, Spina V, Bruscaggin A, Monti S, Cerri M, Cresta S, Fangazio M, Arcaini L, Lucioni M, Marasca R, Thieblemont C, Capello D, Facchetti F, Kwee I, Pileri SA, Foa R, Bertoni F, Dalla-Favera R, Pasqualucci L, Gaidano G (2011) Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. Blood 118: 4930-4934.
  87. Saborit-Villarroya I, Vaisitti T, Rossi D, D'Arena G, Gaidano G, Malavasi F, Deaglio S (2011) E2A is a transcriptional regulator of CD38 expression in chronic lymphocytic leukemia. Leukemia 25: 479-488.
  88. Sandini S, La Valle R, Deaglio S, Malavasi F, Cassone A, De Bernardis F (2011) A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine. FEMS Immunol Med Microbiol 62: 215-224.
  89. Serra S, Horenstein AL, Vaisitti T, Brusa D, Rossi D, Laurenti L, D'Arena G, Coscia M, Tripodo C, Inghirami G, Robson SC, Gaidano G, Malavasi F, Deaglio S (2011) CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 118: 6141-6152.
  90. Vaisitti T, Audrito V, Serra S, Bologna C, Brusa D, Malavasi F, Deaglio S (2011) NAD+-metabolizing ecto-enzymes shape tumor-host interactions: the chronic lymphocytic leukemia model. FEBS Lett 585: 1514-1520.
  91. D'Arena G, D'Auria F, Simeon V, Laurenti L, Deaglio S, Mansueto G, Del Principe MI, Statuto T, Pietrantuono G, Guariglia R, Innocenti I, Martorelli MC, Villani O, De Feo V, Del Poeta G, Musto P (2012) A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. Am J Hematol 87: 628-631.
  92. D'Arena G, Gemei M, Luciano L, D'Auria F, Deaglio S, Statuto T, Bianchino G, Grieco V, Mansueto G, Guariglia R, Pietrantuono G, Martorelli MC, Villani O, Del Vecchio L, Musto P (2012) Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment? J Clin Oncol 30: e327-330.
  93. D'Arena G, Rossi G, Vannata B, Deaglio S, Mansueto G, D'Auria F, Statuto T, Simeon V, De Martino L, Marandino A, Del Poeta G, De Feo V, Musto P (2012) Regulatory T-Cells in Chronic Lymphocytic Leukemia and Autoimmune Diseases. Mediterr J Hematol Infect Dis 4: e2012053.
  94. Dal Bo M, Bomben R, Zucchetto A, Del Poeta G, Gaidano G, Deaglio S, Efremov DG, Gattei V (2012) Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy. Curr Pharm Des 18: 3323-3334.
  95. Isoardo G, Morra I, Chiarle G, Audrito V, Deaglio S, Melcarne A, Junemann C, Naddeo M, Cogoni M, Valentini MC, Limberti A, Faccani F, Malavasi F, Faccani G (2012) Different aquaporin-4 expression in glioblastoma multiforme patients with and without seizures. Mol Med 18: 1147-1151.
  96. Maffei R, Fiorcari S, Bulgarelli J, Martinelli S, Castelli I, Deaglio S, Debbia G, Fontana M, Coluccio V, Bonacorsi G, Zucchini P, Narni F, Torelli G, Luppi M, Marasca R (2012) Physical contact with endothelial cells through beta1- and beta2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. Haematologica 97: 952-960.
  97. Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, Chiaretti S, Del Giudice I, Fabbri G, Bruscaggin A, Spina V, Deambrogi C, Marinelli M, Fama R, Greco M, Daniele G, Forconi F, Gattei V, Bertoni F, Deaglio S, Pasqualucci L, Guarini A, Dalla-Favera R, Foa R, Gaidano G (2012) Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 119: 2854-2862.
  98. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti L, Bruscaggin A, Cerri M, Monti S, Cresta S, Fama R, De Paoli L, Bulian P, Gattei V, Guarini A, Deaglio S, Capello D, Rabadan R, Pasqualucci L, Dalla-Favera R, Foa R, Gaidano G (2012) Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 119: 521-529.
  99. Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Fama R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbo F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foa R, Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G (2012) The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 209: 1537-1551.
  100. Zucchetto A, Vaisitti T, Benedetti D, Tissino E, Bertagnolo V, Rossi D, Bomben R, Dal Bo M, Del Principe MI, Gorgone A, Pozzato G, Gaidano G, Del Poeta G, Malavasi F, Deaglio S, Gattei V (2012) The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia 26: 1301-1312.
  101. Audrito V, Vaisitti T, Serra S, Bologna C, Brusa D, Malavasi F, Deaglio S (2013) Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. Cancer Lett 328: 27-35.
  102. Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L, Jaksic O, Fedele G, Inghirami G, Gaidano G, Malavasi F, Deaglio S (2013) The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica 98: 953-963.
  103. D'Arena G, Simeon V, De Martino L, Statuto T, D'Auria F, Volpe S, Deaglio S, Maidecchi A, Mattoli L, Mercati V, Musto P, De Feo V (2013) Regulatory T-cell modulation by green tea in chronic lymphocytic leukemia. Int J Immunopathol Pharmacol 26: 117-125.
  104. Longhi MS, Robson SC, Bernstein SH, Serra S, Deaglio S (2013) Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states. J Mol Med (Berl) 91: 165-172.
  105. Maffei R, Bulgarelli J, Fiorcari S, Bertoncelli L, Martinelli S, Guarnotta C, Castelli I, Deaglio S, Debbia G, De Biasi S, Bonacorsi G, Zucchini P, Narni F, Tripodo C, Luppi M, Cossarizza A, Marasca R (2013) The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica 98: 1115-1123.
  106. Sava GP, Speedy HE, Di Bernardo MC, Deaglio S, Karabon L, Frydecka I, Woszczyk D, Rossi D, Gaidano G, Mansouri L, Smedby KE, Juliusson G, Rosenquist R, Catovsky D, Houlston RS (2013) rs2072135, a low-penetrance variant for chronic lymphocytic leukaemia? Br J Haematol 162: 221-228.
  107. Vaisitti T, Audrito V, Serra S, Bologna C, Arruga F, Brusa D, Buonincontri R, Gizdic B, Deaglio S (2013) Multiple metamorphoses of CD38 from prognostic marker to disease modifier to therapeutic target in chronic lymphocytic leukemia. Curr Top Med Chem 13: 2955-2964.
  108. Vaisitti T, Serra S, Pepper C, Rossi D, Laurenti L, Gaidano G, Malavasi F, Deaglio S (2013) CD38 signals upregulate expression and functions of matrix metalloproteinase-9 in chronic lymphocytic leukemia cells. Leukemia 27: 1177-1181.
  109. Arruga F, Gizdic B, Serra S, Vaisitti T, Ciardullo C, Coscia M, Laurenti L, D'Arena G, Jaksic O, Inghirami G, Rossi D, Gaidano G, Deaglio S (2014) Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia 28: 1060-1070.
  110. D'Arena G, Calapai G, Deaglio S (2014) Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498. Expert Opin Ther Pat 24: 821-828.
  111. D'Arena G, Laurenti L, Coscia M, Cortelezzi A, Chiarenza A, Pozzato G, Vigliotti ML, Nunziata G, Fragasso A, Villa MR, Grossi A, Selleri C, Deaglio S, La Sala A, Del Poeta G, Simeon V, Aliberti L, De Martino L, Giudice A, Musto P, De Feo V (2014) Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. Leuk Lymphoma 55: 841-847.
  112. Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D, Cattaneo L, Tamborini E, Carobbio A, Rulli E, Deaglio S, Mandala M (2014) PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol.
  113. Rizzo R, Audrito V, Vacca P, Rossi D, Brusa D, Stignani M, Bortolotti D, D'Arena G, Coscia M, Laurenti L, Forconi F, Gaidano G, Mingari MC, Moretta L, Malavasi F, Deaglio S (2014) HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. Haematologica 99: 888-896.
  114. Vaisitti T, Audrito V, Serra S, Buonincontri R, Sociali G, Mannino E, Pagnani A, Zucchetto A, Tissino E, Vitale C, Coscia M, Usai C, Pepper C, Gattei V, Bruzzone S, Deaglio S. The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. Leukemia. 2015;29(2):356-368.
  115. Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D, Cattaneo L, Tamborini E, Carobbio A, Rulli E, Deaglio S*, Mandala M. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol. 2014;25(12):2433-2442.
    * shared last authors
  116. 116. Sava GP, Speedy HE, Di Bernardo MC, Dyer MJ, Holroyd A, Sunter NJ, Marr H, Mansouri L, Deaglio S, Karabon L, Frydecka I, Jamroziak K, Woszczyk D, Juliusson G, Smedby KE, Jayne S, Majid A, Wang Y, Dearden C, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan JM, Houlston RS. Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. Leukemia. 2015;29(3):748-751.
  117. 117. Fiorcari S, Martinelli S, Bulgarelli J, Audrito V, Zucchini P, Colaci E, Potenza L, Narni F, Luppi M, Deaglio S, Marasca R, Maffei R. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. Haematologica. 2015;100(2):253-262.
  118. Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, Coscia M, Maffei R, Rossi D, Wang T, Inghirami G, Rizzi M, Gaidano G, Garcia JG, Wolberger C, Raffaelli N, Deaglio S. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood. 2015;125(1):111-123.
  119. Piva R, Deaglio S*, Fama R, Buonincontri R, Scarfo I, Bruscaggin A, Mereu E, Serra S, Spina V, Brusa D, Garaffo G, Monti S, Dal Bo M, Marasca R, Arcaini L, Neri A, Gattei V, Paulli M, Tiacci E, Bertoni F, Pileri SA, Foa R, Inghirami G, Gaidano G, Rossi D. The Kruppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia. 2015;29(2):503-507.
    * shared first authors
  120. Massi D, Brusa D, Merelli B, Falcone C, Xue G, Carobbio A, Nassini R, Baroni G, Tamborini E, Cattaneo L, Audrito V, S. D, Mandala M. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Ann Oncol. 2015; in press.

 

Silvia Deaglio

Associate Professor

 

 

  • DEPARTMENT Department of Pathology and Laboratory Medicine
    Cornell University
  • COUNTRYNew York